📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-09-01 12:47
510 analysed today
510
Today
133,399
All-time analysed
40,108
Positive
6,279
Negative
79,197
Neutral
7,747
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
127 announcements match the current filters (relevance ≥ 5).
Jubilant Pharmova Receives ₹87.31 Cr GST Show Cause Notice for FY23
Jubilant Pharmova has received a Show Cause Notice from the Assistant Commissioner of Commercial Taxes (Enforcement)-4, Mysore, proposing a total demand of ₹87.31 crore for FY 2022-23. The demand includes ₹33.58 crore in GST, ₹20.15 crore in interest, and ₹33.58 crore in penalty concerning alleged ineligible/excess ITC and E-way bill records. The proposed demand represents approximately 24.9% of the company's TTM net profit of ₹351 crore. Jubilant Pharmova stated it will file a detailed reply contesting the notice on merits and expects no financial or operational impact.
Confidence: HIGH
What changedCommercial tax authorities in Mysore issued a Show Cause Notice proposing a ₹87.31 crore tax, interest, and penalty demand for FY 2022-23.
Why it mattersWhile currently at the show cause stage, the proposed ₹87.31 crore demand is sizable relative to the company's annual net earnings (~25% of TTM PAT of ₹351 crore).
Total proposed demand: Rs. 87.31 CrGST Tax component: Rs. 33.58 CrInterest component: Rs. 20.15 CrPenalty component: Rs. 33.58 CrDemand vs TTM PAT: ~24.9%Financial year involved: 2022-2023
📅 Short termThe company will file a reply contesting the notice; no immediate cash outflow or balance sheet hit is expected until adjudication.
📈 Long termLimited, as input tax credit and E-way bill disputes are typically resolved or appealed through standard quasi-judicial tax channels.
⚠ Risk flags
- Potential liability of ₹87.31 crore if contested grounds are not accepted by tax authorities
- Protracted tax litigation
Key Highlights
Total tax demand proposed of ₹87.31 crore for FY 2022-2023.
Breakdown comprises ₹33.58 crore GST tax, ₹20.15 crore interest, and ₹33.58 crore penalty.
Allegations relate to ineligible ITC, excess ITC availed, and differential tax liability based on E-way bill records.
Notice received on August 31, 2026; company preparing a detailed reply to contest the demand.
👀 What to Watch
Monitor subsequent disclosures on whether the tax authority accepts the company's reply or issues an adverse assessment order.
UBL Invests ₹110 Cr to Commission New 40,000 Cans/Hour Line at Ellora Brewery, Maharashtra
United Breweries Limited (UBL) has announced the commissioning of a new canning line at its Ellora Brewery in Chhatrapati Sambhajinagar, Maharashtra, with an investment of ₹110 crore (~0.97% of TTM revenue). The facility features a capacity of 40,000 cans per hour, making it the brewery's first canning line and among the fastest in UBL's network. The line is expected to become operational in September 2026, subject to statutory approvals, to meet rising consumer demand for canned beer and support premiumization across brands like Kingfisher Strong and London Pilsner. This follows a similar canning expansion commissioned at UBL's Nizam Brewery in Telangana in July 2026.
Confidence: HIGH
What changedUBL added a dedicated high-speed canning line (40,000 cans/hr) to its Ellora Brewery in Maharashtra at a cost of ₹110 crore.
Why it mattersEnables UBL to capture growing consumer preference for canned beer and premium formats in Maharashtra, optimizing brewery utilization and logistics.
Investment Amount: ₹110 croreInvestment vs TTM Revenue: ~0.97%Canning Capacity: 40,000 cans per hourExisting Packaging Capacity: up to 1.5 million cases per monthExpected Commissioning: September 2026
📅 Short termPositive operational update demonstrating continuous capex rollout; minimal immediate impact on quarterly numbers until fully ramped up.
📈 Long termSupports margin expansion and product mix premiumization in a key high-consumption state (Maharashtra).
⚠ Risk flags
- Subject to statutory regulatory approvals before becoming operational
- State-level alcohol taxation and distribution regulations
Key Highlights
₹110 crore investment in Ellora Brewery's first canning line in Maharashtra
Line capacity of 40,000 cans per hour alongside existing packaging capacity of up to 1.5 million cases per month
Scheduled to become operational in September 2026, subject to statutory approvals
Follows previous canning line commissioning at Nizam Brewery, Telangana in July 2026
👀 What to Watch
Track receipt of final statutory approvals and commercial output ramp-up during Q2/Q3 FY27 to gauge volume and mix improvement in Maharashtra.
Jubilant Pharmova Unit Gets ₹105.5 Cr GST Show Cause Notice
Jubilant Pharmova's wholly-owned subsidiary, Jubilant Generics Limited, received a Show Cause Notice from the CGST Division, Roorkee on August 27, 2026. The notice proposes a GST demand of ₹52.75 crore and an equivalent penalty of ₹52.75 crore (totaling ₹105.50 crore plus unquantified interest) for FY 2020-21 and FY 2021-22. The dispute pertains to alleged simultaneous availment of IGST refund under Rule 96 and Advance Authorisation benefits. The company stated the notice is legally incorrect, plans to contest it, and expects no financial impact.
Confidence: HIGH
What changedJubilant Generics received a Show Cause Notice alleging improper IGST refund availment alongside Advance Authorisation benefits, proposing tax and penalties of ₹105.50 crore.
Why it mattersWhile at the show-cause stage, the total quantified claim of ₹105.50 crore is substantial relative to annual profitability (~30% of TTM PAT), though the company intends to contest it vigorously.
GST Tax Demand: ₹52.75 CrPenalty Proposed: ₹52.75 CrInterest Amount: Not QuantifiedTotal Quantified Demand vs TTM PAT: ~30.1%
📅 Short termSubmissions will be filed contesting the show cause notice; no immediate cash outflow is required until adjudication.
📈 Long termLimited operational disruption expected, but potential legal or appellate proceedings could extend over several quarters if the demand is confirmed.
⚠ Risk flags
- Unquantified interest liability in addition to the ₹105.50 crore demand
- Adverse adjudication could impact net earnings if provisions become necessary
Key Highlights
Subsidiary Jubilant Generics receives Show Cause Notice for FY 2020-21 and FY 2021-22.
Demands ₹52.75 crore in GST tax and ₹52.75 crore in penalty, totaling ₹105.50 crore plus interest.
Total quantified demand represents approximately 30.1% of TTM PAT (₹351 crore).
Company is preparing a detailed response to contest the notice before the Joint Commissioner, CGST Roorkee.
👀 What to Watch
Track the subsidiary's response to the tax authorities and subsequent adjudication orders to assess if any liability crystallizes or requires provisioning.
Jubilant Pharmova Gets USFDA Clearance for Commercial Production on Spokane Line 3
Jubilant Pharmova announced that the USFDA has granted approval for commercial batch manufacturing of the first product on Line 3 at its contract manufacturing facility in Spokane, USA. The approval was received on August 21, 2026 (PST) for the new Isolator-based sterile fill-and-finish line operated by subsidiary Jubilant HollisterStier LLC. This operational milestone enables commercial revenue ramp-up in the high-margin sterile injectables CDMO segment.
Confidence: HIGH
What changedUSFDA has approved commercial manufacturing for the initial product on the newly installed Line 3 at the Spokane sterile injectables site.
Why it mattersCommercialization of Line 3 directly supports the company's strategy to expand high-margin CDMO sterile injectables capacity and offset generic pricing pressures.
Approval receipt date: August 21, 2026Facility location: Spokane, WA, U.S.A.Manufacturing line: Line 3 (Isolator-based fill & finish)TTM Revenue context: ₹8,607 Cr
📅 Short termProvides positive sentiment by de-risking regulatory timelines for newly installed sterile fill-finish infrastructure.
📈 Long termSupports structural top-line growth and margin expansion by shifting business mix toward sterile injectables CDMO contracts.
⚠ Risk flags
- Pace of commercial volume ramp-up and client demand uptake
- Ongoing regulatory compliance across USFDA inspections
Key Highlights
USFDA approval received for commercial batch manufacturing of the first product on Line 3.
Line 3 is an advanced Isolator-based fill-and-finish line located in Spokane, WA, USA.
Approval received on August 21, 2026 (12:46 PM PST / August 22, 2026, 01:16 AM IST).
Operated by Jubilant HollisterStier LLC, a step-down wholly owned subsidiary under Jubilant Pharma Limited.
👀 What to Watch
Track the pace of commercial batch ramp-up on Line 3 in upcoming quarterly updates, as well as progress on the Montreal sterile capacity expansion.
JUBLFOOD Q1FY27 Concall: Popeyes LFL Grows 45%, FY27 Capex Guided at ₹750-900 Cr
Jubilant FoodWorks released the transcript of its Q1FY27 earnings conference call. Management highlighted strong acceleration in Popeyes with like-for-like (LFL) sales growth reaching 45% in Q1FY27 compared to 9.2% in Q1FY26. Annual capex guidance for FY27 was reiterated at ₹750-900 crore (7.6%-9.1% of TTM revenue of ₹9,846 crore), focused on store additions, dine-in upgrades, and tech. The company is actively executing a 3-pillar strategy to revive dine-in/takeaway demand and aims for 5%-7% LFL growth for the full year.
Confidence: HIGH
What changedJubilant FoodWorks submitted the full verbatim transcript of its Q1FY27 analyst conference call held on August 13, 2026.
Why it mattersProvides operational insights into Popeyes emerging as a high-growth growth engine, dine-in channel interventions, store-level productivity gains, and FY27 capital expenditure plans.
Popeyes Q1FY27 LFL Growth: 45%Popeyes Q1FY26 LFL Growth: 9.2%FY27 Capex Guidance: ₹750 - ₹900 crCapex vs TTM Revenue: ~7.6% - 9.1%Consolidated Personnel Cost YoY Increase: 15.6%
📅 Short termThe concall transcript confirms operational focus on scaling Popeyes and rolling out tactical promotions (e.g. Wednesday dine-in deals) to counter delivery aggregator pricing pressures.
📈 Long termSustained execution on Popeyes expansion, Turkey business integration, and product premiumization will determine if JFL achieves its target of 200 bps EBITDA margin improvement.
⚠ Risk flags
- Cannibalization and dining softness due to lower minimum order values on delivery aggregators
- Wage inflation and commodity price volatility (dairy and poultry)
Key Highlights
Popeyes recorded 45% LFL sales growth in Q1FY27, accelerating from 9.2% in Q1FY26.
FY27 capex guidance maintained at ₹750 crore to ₹900 crore (~8% of TTM revenue).
Personnel costs rose 12% YoY on a standalone basis and 15.6% on a consolidated basis.
Targeting full-year LFL growth recovery toward the 5%-7% guided range.
👀 What to Watch
Track same-store sales growth (LFL) trends in Q2FY27 and the pace of Popeyes store additions along with dine-in traffic stabilization.
₹189.2 Cr Stake Buy: Jubilant Ingrevia to Acquire 40% in Zettaone Technologies
Jubilant Ingrevia has entered into a binding term sheet to acquire a 40% strategic equity stake in Zettaone Technologies India Pvt. Ltd. for approximately ₹189.2 crore in cash. Zettaone is an electronics design and manufacturing platform (EDMS) with FY26 turnover of ₹98.1 crore (growing from ₹51.1 crore in FY24). The transaction will be completed in two tranches—tranche 1 by November 2026 and tranche 2 by September 2027—making Zettaone an associate company. This investment aligns with Jubilant Ingrevia's 'Pinnacle' strategy to build an integrated value chain across electronics and semiconductor spaces.
Confidence: HIGH
What changedJubilant Ingrevia approved acquiring a 40% strategic stake in EDMS platform Zettaone Technologies for ₹189.2 crore.
Why it mattersEnables the specialty chemical and CDMO player to expand into electronics and semiconductor manufacturing services, capturing higher-value deep-tech supply chains.
Acquisition Cost: ₹189.2 CrStake Acquired: 40%Target FY26 Turnover: ₹98.1 CrTarget FY25 Turnover: ₹79.1 CrCost vs Net Worth: ~7.2%Tranche 1 Completion: November 2026
📅 Short termPositive sentiment as the company takes a concrete step toward expanding its high-margin semiconductor and EDMS footprint without straining its balance sheet.
📈 Long termEnhances long-term capability to provide integrated high-tech hardware, PCB design, and semiconductor chemical solutions, supporting the company's Pinnacle growth roadmap.
⚠ Risk flags
- Integration risk and business model alignment between chemical CDMO and electronics hardware design
- Two-tranche closing timeline extends execution out to September 2027
Key Highlights
Acquisition of 40% strategic equity stake in Zettaone Technologies for ₹189.2 crore in cash
Target entity generated FY26 turnover of ₹98.1 crore, up from ₹79.1 crore in FY25 and ₹51.1 crore in FY24
Two-tranche completion schedule: Tranche 1 by November 2026 and Tranche 2 by September 2027
Transaction represents ~7.2% of Jubilant Ingrevia's net worth (₹2,640 crore) and ~1.6% of its market cap
👀 What to Watch
Track the closure of Tranche 1 by November 2026 and monitor synergy disclosures regarding CDMO cross-selling into semiconductor and electronics sectors in upcoming earnings calls.
Jubilant Ingrevia to Acquire 40% Stake in Zettaone for ₹189.2 Cr
Jubilant Ingrevia has entered into a binding term sheet to acquire a 40% strategic equity stake in Zettaone Technologies India Private Limited for approximately ₹189.2 crore in cash. The acquisition will be completed in two tranches, with the first closing expected by November 2026 and the second by September 2027, making Zettaone an associate company. Zettaone operates in electronics design and manufacturing (EDMS), posting revenue of ₹98.1 crore in FY26, up from ₹79.1 crore in FY25 and ₹51.1 crore in FY24. This transaction advances Jubilant's 'Pinnacle' strategy into the semiconductor and electronics value chain.
Confidence: HIGH
What changedJubilant Ingrevia approved a binding term sheet to acquire a 40% associate stake in deep-tech EDMS provider Zettaone Technologies for ₹189.2 crore.
Why it mattersEnables forward integration into the electronics and semiconductor hardware ecosystem, complementing the company's existing semiconductor chemical CDMO initiatives under its Pinnacle growth strategy.
Acquisition cost: ₹ 189.2 Cr.Stake acquired: 40%Target FY26 turnover: ₹ 98.1 Cr.Tranche 1 completion date: November 2026Tranche 2 completion date: September 2027Deal size vs Net Worth: ~7.2%
📅 Short termProvides positive strategic momentum; investors will track execution of definitive agreements and the Tranche 1 closure in November 2026.
📈 Long termPositioned to create synergies across semiconductor chemicals and high-speed PCB/electronics design for aerospace, defence, and automotive sectors over FY27–FY28.
⚠ Risk flags
- Two-stage acquisition timeline extending until September 2027 carries execution and integration timing risks.
- Target valuation (~4.8x FY26 sales) requires sustained high revenue growth and operating margin expansion.
Key Highlights
Acquiring a 40% strategic equity stake in Zettaone Technologies for an aggregate cash consideration of ₹189.2 crore.
Target company revenue grew 92% over two years, from ₹51.1 crore in FY24 to ₹79.1 crore in FY25 and ₹98.1 crore in FY26.
Two-tranche closing schedule: Tranche 1 by November 2026 and Tranche 2 by September 2027.
Deal value of ₹189.2 crore represents ~7.2% of Jubilant Ingrevia's net worth (₹2,640 crore) and ~4.1% of TTM revenue (₹4,651 crore).
👀 What to Watch
Monitor the definitive agreement signing and closing of Tranche 1 by November 2026, alongside management commentary on synergistic customer cross-selling between CDMO chemicals and EDMS.
14.1% Revenue Growth in Q1 FY27; Popeyes LFL Surges 40%+
Jubilant Foodworks reported a 14.1% YoY increase in consolidated revenue to ₹2,570 crore for Q1 FY27, with EBITDA growing 14.2% to ₹504 crore. Domino's India saw a recovery in Like-for-Like (LFL) growth to 2.5% (up from 0.2% in the previous quarter) alongside 6.5% order growth. Popeyes has emerged as a significant growth engine, delivering 40%+ LFL growth for the third consecutive quarter and 97% revenue growth. The company added 76 net new stores, bringing its global network to 3,712 stores across six markets.
Confidence: HIGH
What changedDomino's India LFL growth improved to 2.5% from 0.2% in the previous quarter, and Dunkin' operations have been reclassified as discontinued.
Why it mattersThe results demonstrate that Jubilant is successfully diversifying its growth beyond Domino's through Popeyes and international markets, while maintaining strong gross margins despite inflationary pressures.
Consolidated Revenue (Q1): ₹2,570 crRevenue vs TTM Revenue: 26.9%Popeyes LFL Growth: 40%+Domino's India LFL Growth: 2.5%Standalone Gross Margin: 75.5%Net Store Additions: 76
📅 Short termThe stock may see positive sentiment as LFL growth for the core Domino's brand shows signs of recovery and Popeyes continues to scale rapidly.
📈 Long termThe company is structurally shifting toward a multi-brand food-service platform, reducing concentration risk on Domino's India and leveraging its international footprint in Eurasia.
⚠ Risk flags
- Hyperinflationary accounting (IAS 29) impacts reported profitability in Turkey
- Slow recovery in the Dine-In (DITA) channel
- High competitive intensity in the QSR chicken and coffee segments
Key Highlights
Consolidated revenue grew 14.1% YoY to ₹2,570 crore, representing approximately 27% of TTM revenue.
Popeyes India revenue grew 97% YoY with LFL growth exceeding 40% for the third straight quarter.
Domino's India delivery channel revenue grew 12.1% YoY, now accounting for 76.1% of the sales mix.
Standalone gross margins expanded by 133 bps to 75.5% through supply chain efficiencies and selective pricing.
DP Eurasia (Turkey, Georgia, Azerbaijan) delivered 28.2% revenue growth and upstreamed ₹52 crore in dividends over 9 months.
👀 What to Watch
Monitor the recovery of the Dine-In and Take-Away (DITA) channel, which is currently undergoing a turnaround program involving 400 store upgrades, and track the progress of Popeyes toward its ₹1,000 crore revenue target.
JUBLFOOD Q1 FY27: Standalone Revenue Grows 9.2% YoY to ₹1,848.9 Cr; Dunkin' Rights Not Renewed
Jubilant Foodworks reported a steady 9.2% YoY growth in standalone revenue for Q1 FY27, reaching ₹1,848.9 cr. Standalone PAT saw a modest increase of 4.4% YoY to ₹69.6 cr, while the company officially classified Dunkin' India as a discontinued operation following the board's decision not to renew brand rights. Total comprehensive income surged to ₹206.3 cr, significantly aided by a ₹136.7 cr gain in other comprehensive income. Operating expenses rose 9.5% YoY, tracking closely with revenue growth and reflecting continued inflationary pressures in the QSR segment.
Confidence: HIGH
What changedThe company has formally decided not to renew the rights for the Dunkin' brand in India, reclassifying it as a discontinued operation, while maintaining high single-digit revenue growth in its core business.
Why it mattersThe exit from Dunkin' allows the company to focus resources on more profitable or higher-growth segments like Popeyes, though the immediate impact is a slight drag on the bottom line from discontinued losses.
Standalone Revenue (Q1 FY27): ₹1,848.85 crRevenue vs TTM Revenue: 19.4%Standalone PAT: ₹69.62 crDunkin' Discontinued Loss: ₹3.17 crOther Comprehensive Income: ₹136.71 cr
📅 Short termThe stock may see neutral to slightly cautious movement as the market digests the modest profit growth and the strategic exit from the Dunkin' brand.
📈 Long termThe long-term outlook depends on the company's ability to scale Popeyes to a meaningful size and achieve its stated goal of 200 bps margin expansion by reducing drags from emerging brands.
⚠ Risk flags
- Rising operating expenses (up 9.5% YoY)
- Execution risk in scaling new brands after Dunkin' exit
- Sensitivity to discretionary consumer spending
Key Highlights
Standalone Revenue from operations increased to ₹1,848.85 cr from ₹1,692.91 cr in the year-ago quarter.
Net Profit for the period stood at ₹69.62 cr, representing a 4.4% growth over Q1 FY26's ₹66.70 cr.
Loss from discontinued operations (Dunkin' brand) narrowed to ₹3.17 cr compared to a loss of ₹6.81 cr in Q1 FY25.
Total expenses for the quarter rose to ₹1,760.53 cr, up from ₹1,607.91 cr in the previous year.
Other Comprehensive Income contributed ₹136.71 cr to the total comprehensive income of ₹206.33 cr.
👀 What to Watch
Investors should monitor the management's commentary on the strategic exit from the Dunkin' brand and the subsequent reallocation of capital toward Popeyes and Hong's Kitchen. Key metrics to watch in the full investor presentation include Like-for-Like (LFL) growth for Domino's India and the progress of the 200 bps EBITDA margin improvement plan.
18% Revenue Growth in Q1 FY27; Rs 50 Cr Capex for 30,000 MTPA Expansion
JUBLCPL reported a strong 18% YoY revenue growth to Rs 523.2 Cr in Q1 FY27, primarily driven by a 27% surge in its Performance Polymers & Chemicals segment. While PAT grew 4% to Rs 46.1 Cr, EBITDA margins contracted by 135 bps to 13.0% due to higher input costs and a weak monsoon impacting the Agri segment. The company is executing a Rs 50 Cr brownfield expansion to add 30,000 MTPA capacity for SBR Latex, with completion expected by Q3 FY27. Furthermore, the demerger of the Agri business is progressing, with a court-convened meeting scheduled for September 05, 2026.
Confidence: HIGH
What changedThe company reported its Q1 FY27 financial results and provided a concrete timeline for its 30,000 MTPA capacity expansion and the legal process for its Agri business demerger.
Why it mattersThe demerger will allow the company to focus on high-margin specialty chemicals, while the capacity expansion into SBR Latex targets the high-growth construction chemicals market, potentially improving long-term margins.
Q1 FY27 Revenue: Rs 523.2 CrYoY Revenue Growth: 18%Capex vs TTM Revenue: ~6.06%EBITDA Margin: 13.0%Proposed Capacity Addition: 30,000 MTPA
📅 Short termPositive sentiment expected due to strong top-line growth in the core polymer segment and clarity on the demerger timeline.
📈 Long termStructural shift towards high-margin specialty chemicals and a leaner corporate structure post-demerger could lead to a business re-rating.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Input cost volatility (VAM prices)
- Weak monsoon impacting Agri segment demand
- Geopolitical disruptions affecting export logistics
Key Highlights
Consolidated revenue increased 18% YoY to Rs 523.2 Cr in Q1 FY27
Performance Polymers & Chemicals segment revenue grew 27% to Rs 381.5 Cr
Rs 50 Cr brownfield capex sanctioned for 30,000 MTPA capacity addition at Vadodara
Agri business EBIT declined 52% YoY to Rs 6.4 Cr due to subdued demand from uneven monsoons
NCLT directed a meeting of shareholders and creditors on September 05, 2026, for the Agri business demerger
👀 What to Watch
Monitor the commissioning of the SBR Latex expansion by the end of Q3 FY27 and the outcome of the shareholder vote on the Agri business demerger on September 05.
JUBLCPL Q1 FY27 Net Profit up 7.5% to ₹45.5 Cr; Demerger Meeting Set for Sept 5
JUBLCPL reported a strong 19.5% YoY growth in revenue to ₹518.80 Cr for Q1 FY27, driven by a 29.8% surge in the Performance Polymers & Chemicals segment. Net profit grew 7.5% YoY to ₹45.53 Cr, despite a significant 40% increase in raw material costs which reached ₹318.95 Cr. A key development is the NCLT-directed meeting on September 5, 2026, to approve the demerger of the Agri Division into a separate entity. The company's Q1 revenue alone represents approximately 62.8% of its previously reported TTM revenue, indicating a sharp scale-up.
Confidence: HIGH
What changedThe company reported its Q1 FY27 financial results and confirmed the regulatory timeline for its strategic demerger of the agri-business.
Why it mattersThe strong growth in the Performance Polymers segment validates the company's strategy to focus on high-margin chemicals, while the demerger will simplify the corporate structure and allow specialized focus for each business unit.
Revenue (Q1 FY27): ₹518.80 CrNet Profit (Q1 FY27): ₹45.53 CrQ1 Revenue vs TTM Revenue: 62.8%Polymers Segment Revenue: ₹394.02 CrDemerger Meeting Date: September 5, 2026
📅 Short termThe stock may react positively to the double-digit revenue growth and the concrete timeline provided for the demerger process.
📈 Long termThe demerger of the lower-margin agri-business could lead to a valuation re-rating of the remaining polymers and chemicals business over the next 12-18 months.
⚠ Risk flags
- Significant increase in raw material costs (VAM prices)
- Execution risk related to the demerger process
- Moderate pricing power in consumer segments
Key Highlights
Revenue from operations increased 19.5% YoY to ₹518.80 Cr from ₹434.12 Cr.
Net Profit rose to ₹45.53 Cr compared to ₹42.35 Cr in the corresponding quarter of the previous year.
Performance Polymers & Chemicals segment revenue grew to ₹394.02 Cr, now contributing 76% of total segment revenue.
NCLT order dated July 8, 2026, mandates shareholder and creditor meetings on September 5, 2026, for the Agri Division demerger.
Cost of materials consumed spiked to ₹318.95 Cr from ₹227.83 Cr YoY, reflecting input cost pressures.
👀 What to Watch
Investors should monitor the outcome of the September 5, 2026, meeting regarding the demerger, as this structural change aims to unlock value in the high-growth polymers business.
17% Revenue Growth in Q1 FY27; EBITDA Margins Contract to 11.9% on Supply Gaps
Jubilant Pharmova reported Q1 FY27 revenue of Rs 2,229 Cr, a 17% YoY increase driven by broad-based growth across segments, particularly CDMO Sterile Injectables (+34%). However, EBITDA fell 11% YoY to Rs 268 Cr, with margins contracting by 385 bps to 11.9% due to the unavailability of high-margin SPECT radiopharmaceuticals and remediation costs at the Montreal facility. Reported PAT declined 45% YoY to Rs 56 Cr. Management expects margin recovery in H2 FY27 as SPECT products return to market and Spokane Line 3 continues to ramp up.
Confidence: HIGH
What changedThe company achieved strong top-line growth but faced a significant profitability squeeze due to temporary product supply gaps and regulatory remediation expenses.
Why it mattersThe results highlight a transition phase where new capacity (Spokane Line 3) is scaling well, but legacy regulatory issues (Montreal) and supply chain gaps in Radiopharma are weighing on consolidated margins.
Q1 Revenue: Rs 2,229 CrEBITDA Margin: 11.9%PAT Growth (YoY): -45%Net Debt/EBITDA: 1.8xUS Revenue Contribution: 81%Spokane Line 3 Revenue Growth: 43%
📅 Short termThe stock may face pressure due to the sharp decline in PAT and margins, though the 17% revenue growth and positive outlook for H2 FY27 provide some support.
📈 Long termStructural growth remains tied to the CDMO ramp-up and the expansion of the PET radiopharmacy network to 9 sites by FY28, which could re-rate margins once Montreal issues are resolved.
⚠ Risk flags
- FDA warning letter remediation at Montreal facility
- Increased leverage (Net Debt/EBITDA at 1.8x)
- Pricing pressure in API and Generics segments
Key Highlights
Revenue grew 17% YoY to Rs 2,229 Cr, with CDMO Sterile Injectables leading growth at 34% YoY (Rs 496 Cr).
EBITDA margins contracted to 11.9% from 15.8% YoY, impacted by SPECT product unavailability and Montreal remediation costs.
Net Debt to EBITDA ratio increased to 1.8x in June 2026 from 1.5x in March 2026 due to ongoing growth investments.
Spokane Line 3 revenue grew 43% YoY to Rs 494 Cr with EBITDA margins expanding 100 bps to 24%.
US-based manufacturing accounts for 78% of US revenue, positioning the company to benefit from new US tariffs on non-US innovators.
👀 What to Watch
Monitor the successful release of SPECT radiopharmaceutical batches in Q2 FY27 and the stabilization of the Montreal facility following the FDA warning letter. Watch for the commencement of technology transfer revenues from the newly installed Spokane Line 4 in Q4 FY27.
Q1 FY27 Revenue at Rs 2,229 Cr; PBT Declines 51% Sequentially to Rs 86.4 Cr
Jubilant Pharmova reported a consolidated revenue of Rs 2,229.4 Cr for Q1 FY27, representing a 17.3% YoY growth but a 2.6% sequential decline. Profit Before Tax (PBT) fell sharply to Rs 86.4 Cr from Rs 176 Cr in the previous quarter, primarily due to margin compression in the CDMO - Sterile Injectables segment. The Generics business continues to be a drag, reporting an EBIT loss of Rs 10.1 Cr. Radiopharma remains the primary driver, contributing Rs 1,022.1 Cr to the top line with stable margins.
Confidence: HIGH
What changedThe company released its Q1 FY27 financial results, showing a significant sequential drop in operational profitability despite year-on-year revenue growth.
Why it mattersThe sharp decline in CDMO margins and ongoing losses in Generics offset the steady performance of the Radiopharma business, raising concerns about near-term operational efficiency.
Consolidated Revenue (Q1 FY27): Rs 2,229.4 CrRevenue vs TTM Revenue: 34.1%Consolidated PBT: Rs 86.4 CrCDMO Segment Profit: Rs 7.3 CrGenerics Segment EBIT: Rs -10.1 CrFinance Costs: Rs 54.2 Cr
📅 Short termThe stock may face downward pressure in the short term due to the sequential decline in PBT and the sharp margin contraction in the CDMO segment.
📈 Long termLong-term value depends on the successful ramp-up of the Spokane and Montreal facilities and the strategic shift toward high-margin CDMO and Radiopharma segments.
⚠ Risk flags
- Margin compression in CDMO - Sterile Injectables
- Continued losses in the Generics segment
- High finance costs relative to operating profit
Key Highlights
Consolidated revenue grew 17.3% YoY to Rs 2,229.4 Cr, driven by Radiopharma and CDMO segments.
CDMO - Sterile Injectables segment profit plummeted to Rs 7.3 Cr from Rs 55.9 Cr in Q4 FY26.
Generics segment reported an EBIT loss of Rs 10.1 Cr compared to a profit of Rs 17.4 Cr in the previous quarter.
Radiopharma segment revenue stood at Rs 1,022.1 Cr, accounting for 45.9% of total segment revenue.
Finance costs remained high at Rs 54.2 Cr, impacting the overall bottom line.
👀 What to Watch
Investors should monitor the recovery of margins in the CDMO - Sterile Injectables segment and the execution of the Montreal capacity expansion scheduled for H2 FY26. The continued underperformance of the Generics segment remains a key area of concern for overall profitability.
EUR 116 Million Corporate Guarantee Released Following Subsidiary Debt Refinancing
Jubilant Foodworks Limited (JFL) has announced the release of corporate guarantees totaling EUR 116.085 million (approx. ₹1,060 cr). This follows the successful refinancing of debt by its wholly-owned subsidiary, Jubilant FoodWorks Netherlands B.V. (JFN), which secured a new facility of EUR 111.1 million. The release of these guarantees significantly reduces the parent company's contingent liabilities, which previously represented approximately 44% of its net worth (₹2,402 cr). This move is part of the company's ongoing effort to optimize its international capital structure following the DP Eurasia acquisition.
Confidence: HIGH
What changedA large contingent liability (corporate guarantee) has been removed from JFL's balance sheet after its Netherlands subsidiary successfully refinanced its existing debt.
Why it mattersThis improves the parent company's risk profile by reducing off-balance sheet exposure and demonstrates the subsidiary's ability to independently manage its debt obligations.
Released Guarantee Value: EUR 116,085,000New Facility Amount: EUR 111,100,000Guarantee vs Net Worth: ~44%Consolidated Debt: ₹3,308 Cr
📅 Short termThe news is likely to be viewed positively by the market as it confirms the execution of the refinancing plan announced in June 2026, reducing financial risk.
📈 Long termReflects disciplined financial management of international operations; successful refinancing often leads to better interest terms and improved consolidated margins over time.
⚠ Risk flags
- Currency risk associated with EUR-denominated debt facilities
Key Highlights
Corporate guarantees aggregating to EUR 116,085,000 have been revoked and released.
Subsidiary Jubilant FoodWorks Netherlands B.V. availed a new facility of EUR 111,100,000.
The refinancing was completed and the event recorded on August 05, 2026.
The released guarantee amount is equivalent to approximately 44% of the company's reported net worth of ₹2,402 cr.
👀 What to Watch
Investors should monitor the upcoming quarterly results to see the impact of this refinancing on consolidated interest costs and the overall debt-to-equity ratio.
Q1 Net Profit ₹166 Cr; Revenue up 10% to ₹5,917 Cr; Premium Volumes Grow 7%
United Breweries (UBL) reported a 10% YoY growth in gross revenue to ₹5,917.45 Cr for Q1 FY27, driven by strong premiumization trends. However, net profit declined 9.4% YoY to ₹166.39 Cr, primarily due to a 300bps gross margin impact from Middle East sourcing disruptions. EBITDA margins recovered sequentially to 10.9% from 6.5% in Q4 FY26, though they remain 35bps lower than the previous year. Free Operating Cash Flow (FOCF) showed significant strength, rising 38% to ₹548 Cr.
Confidence: HIGH
What changedUBL reported its Q1 FY27 results, showing a successful push into premium brands but facing temporary margin compression from geopolitical supply chain issues.
Why it mattersThe results confirm that UBL's premiumization strategy is working (premium margins are now accretive), but the business remains sensitive to external sourcing shocks and state-level regulatory changes.
Gross Revenue (Q1): ₹5,917.45 CrNet Profit (Q1): ₹166.39 CrEBITDA Margin: 10.9%Free Operating Cash Flow: ₹548 CrQ1 Revenue vs TTM Revenue: 43.4%Contingent Liability (CCI Penalty): ₹751.83 Cr
📅 Short termThe stock may see mixed reactions as the market weighs strong top-line growth and premium volume gains against the 9% dip in net profit and margin pressure.
📈 Long termStructural growth remains intact through premiumization and capacity expansion in high-growth states like UP and Telangana, though regulatory excise risks persist.
⚠ Risk flags
- Geopolitical sourcing risks impacting margins
- Regulatory uncertainty regarding state excise policies
- Unquantified legal risk from the ongoing CCI penalty appeal
Key Highlights
Gross Revenue from operations reached ₹5,917.45 Cr, a 10% increase over ₹5,378.88 Cr in Q1 FY26.
Premium segment volumes grew 7% All-India, led by Heineken Silver (+28%) and Kingfisher Ultra (+11%).
Free Operating Cash Flow (FOCF) improved by 38% to ₹548 Cr, supported by disciplined working capital management.
Gross Profit margin stood at 41.0%, down 155bps YoY, including a 300bps negative impact from Middle East war-related sourcing issues.
Commissioned a new canning line in Telangana; greenfield expansion in Uttar Pradesh remains on track.
👀 What to Watch
Monitor the stabilization of sourcing costs as the company navigates Middle East supply chain disruptions. Investors should also track the progress of the Uttar Pradesh greenfield facility and the final outcome of the ₹751.83 Cr CCI penalty currently sub judice in the Supreme Court.
JUBLCPL Schedules Sept 5 Creditors Meeting for Agri-Business Demerger Approval
Jubilant Agri and Consumer Products Limited (JUBLCPL) has scheduled a meeting of its unsecured creditors on September 05, 2026, to seek approval for the demerger of its Agri-business into Jubilant Agri Solutions Limited. This follows the NCLT Allahabad Bench order dated July 08, 2026, and previous 'no objection' clearances from BSE and NSE in April 2026. The restructuring is a strategic move to separate the volatile agri-business from the high-margin Performance Polymers segment, which currently contributes to a TTM revenue of Rs 825 Cr. Creditors with outstanding debt exceeding Rs 1,00,000 as of March 31, 2026, are eligible to participate in the voting process.
Confidence: HIGH
What changedThe company has progressed to the creditor-approval stage of its corporate restructuring, following the NCLT's first motion order.
Why it mattersThe demerger is central to the company's strategy to focus on high-margin Performance Polymers and Adhesives, where it is currently adding 30,000 MTPA of capacity.
Meeting Date: September 05, 2026Creditor Debt Threshold: > Rs 1,00,000TTM Revenue: Rs 825 CrExchange No-Objection Date: April 17, 2026NCLT Order Date: July 08, 2026
📅 Short termThe announcement confirms the restructuring timeline is on track, which may support neutral-to-positive sentiment as the process moves toward final NCLT approval.
📈 Long termThe demerger is expected to unlock value by allowing specialized management focus and capital allocation for the high-growth polymers segment.
⚠ Risk flags
- Regulatory approval delays
- Potential opposition from creditors
- Execution risk during business separation
Key Highlights
Meeting of unsecured creditors scheduled for September 05, 2026, at 12:30 PM in Gajraula, UP.
Notices dispatched to creditors with outstanding debt exceeding Rs 1,00,000 as of the March 31, 2026 cut-off date.
BSE and NSE issued 'no objection' letters for the proposed scheme on April 17, 2026.
The demerger involves transferring the Agri-business to the resulting company, Jubilant Agri Solutions Limited.
Fairness opinion and share entitlement reports for the scheme were finalized on November 01, 2025.
👀 What to Watch
Investors should monitor the outcome of the creditors' meeting on September 05, 2026, and the subsequent final NCLT hearing for the effective date of the demerger.
JUBLCPL Schedules Sept 5 Shareholder Meeting for Agri-Business Demerger Approval
Jubilant Agri and Consumer Products Limited (JUBLCPL) has scheduled an NCLT-convened meeting on September 05, 2026, to seek shareholder approval for the demerger of its agri-business into Jubilant Agri Solutions Limited (JASL). This follows the NCLT order dated July 08, 2026, and previous 'no objection' clearances from BSE and NSE in April 2026. The demerger is a strategic move to separate the agri-business from the high-margin Performance Polymers and Adhesives segment. Shareholders as of the August 06, 2026, cut-off date are eligible to participate in the voting process.
Confidence: HIGH
What changedThe company has progressed from the initial filing stage to the formal shareholder approval stage for its planned demerger, following NCLT directions.
Why it mattersThis structural reorganization aims to unlock value by separating the agri-business from the polymers segment, allowing for specialized management focus and potentially better capital allocation for the TTM Rs 825 Cr revenue business.
Meeting Date: September 05, 2026Cut-off Date: August 06, 2026TTM Revenue: Rs 825 CrNCLT Order Date: July 08, 2026Fairness Opinion Date: November 01, 2025
📅 Short termThe stock may experience increased interest leading up to the August 06 cut-off date and the September 05 meeting as the market reacts to the progress of the value-unlocking demerger.
📈 Long termThe demerger could lead to a structural re-rating if the remaining polymers business achieves higher margins and the new agri entity successfully expands into bulk fertilizers.
⚠ Risk flags
- Regulatory delays in final NCLT approval
- Execution risks during asset/liability separation
- Input cost volatility (VAM prices) for the polymer segment
Key Highlights
Shareholder meeting scheduled for September 05, 2026, at 11:30 A.M. in Gajraula, UP.
Cut-off date for voting eligibility is set for August 06, 2026.
Remote e-voting window opens on September 02, 2026, and closes on September 04, 2026.
The demerger follows the NCLT Allahabad Bench order dated July 08, 2026.
BSE and NSE provided their 'no objection' letters for the scheme on April 17, 2026.
👀 What to Watch
Monitor the voting results of the September 05 meeting and the subsequent second motion petition to the NCLT for final sanction. Investors should also watch for the specific share entitlement ratio and the listing timeline for the new agri-business entity.
Jubilant Ingrevia Q1 FY27: Rs 1,300 Cr Revenue Hits 15-Quarter High; EBITDA Up 36% YoY
Jubilant Ingrevia reported a strong start to FY27 with revenue growing 25% YoY to Rs 1,300 crore, a 15-quarter high. EBITDA increased 36% YoY to Rs 209 crore, driven by a massive 240% surge in the Chemical Intermediates segment and steady 26% margins in Specialty Chemicals. The company confirmed its 'Pinnacle 345' growth strategy, supported by a $300M+ 5-year CDMO contract with take-or-pay protection and a pipeline of 100+ molecules with Rs 3,500+ crore peak revenue potential. Management expects sequential improvements throughout the year as new capacities like the Gajraula MPP commission by late 2026.
Confidence: HIGH
What changedThe company has moved from a period of margin compression to a volume-led recovery across all segments, particularly in Chemical Intermediates and Nutrition.
Why it mattersThe strong performance validates the company's transition toward high-margin Specialty Chemicals and CDMO services, reducing its historical dependence on cyclical commodity chemicals.
Q1 Revenue: Rs 1,300 crQ1 Revenue vs TTM Revenue: ~29.6%YoY EBITDA Growth: 36%CDMO Peak Revenue Potential: Rs 3,500+ crSpecialty Chemicals EBITDA Margin: 26%Large CDMO Contract Value: $300M+
📅 Short termThe stock may see positive sentiment following the 15-quarter high revenue and significant EBITDA recovery in the intermediates segment.
📈 Long termThe 'Pinnacle 345' plan to triple revenue and quadruple EBITDA over 5 years is supported by a strong CDMO funnel and upcoming high-tech semiconductor chemical facilities.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Pricing pressure in Pyridine and Picolines
- Geopolitical disruptions in the Middle East affecting supply chains
- Cyclicality in the Acetyls portfolio
Key Highlights
Revenue reached Rs 1,300 crore, representing 25% YoY growth and a 15-quarter high.
Chemical Intermediates EBITDA surged 240% YoY to Rs 57 crore due to robust demand and price escalations.
CDMO pipeline expanded to 100+ molecules with a peak revenue potential of Rs 3,500+ crore.
Confirmed $300M+ 5-year CDMO contract includes full take-or-pay protection for the company.
New Multi-Purpose Plant (MPP) at Gajraula remains on track for commissioning by the end of calendar year 2026.
👀 What to Watch
Monitor the execution timeline of the Gajraula MPP and the Bharuch CDMO Agro plant, as these are critical to fulfilling the $300M+ contract and achieving the 'Pinnacle 345' revenue targets.
41% PAT Growth: Jubilant Ingrevia Reports 15-Quarter High Revenue of ₹1,300 Cr in Q1 FY27
Jubilant Ingrevia delivered a strong Q1 FY27 with revenue growing 25% YoY to ₹1,300 crore, driven by robust demand in Chemical Intermediates and Nutrition segments. PAT surged 41% YoY to ₹106 crore, while EBITDA margins expanded to 16% from 15% in the previous year. The company reported a significant recovery in Chemical Intermediates EBITDA, which grew 240% YoY to ₹57 crore. Management highlighted a robust CDMO/Fine Chemicals pipeline of 100+ molecules with a peak revenue potential exceeding ₹3,500 crore.
Confidence: HIGH
What changedThe company has transitioned from a period of margin pressure to strong growth, achieving its highest revenue in nearly four years and significant margin recovery in the Intermediates segment.
Why it mattersThe results validate the company's diversified business model and its ability to pass through input costs, while the expanding CDMO pipeline provides long-term revenue visibility beyond cyclical chemical products.
Q1 FY27 Revenue: ₹1,300 CrRevenue vs TTM Revenue: 29.6%PAT Growth (YoY): 41%EBITDA Margin: 16%Pipeline Peak Revenue Potential: ₹3,500+ CrFY27 Lean Savings Target: ₹100 Cr
📅 Short termThe stock is likely to react positively to the 15-quarter high revenue and the sharp 240% YoY jump in Chemical Intermediates EBITDA.
📈 Long termThe 'Pinnacle 345' plan to triple revenue and quadruple EBITDA over 5 years remains the structural driver, supported by entry into high-tech semiconductor chemicals.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Pricing pressure in Pyridine
- Geopolitical disruptions in the Middle East affecting supply chains
- Cyclicality in the Acetyls portfolio
Key Highlights
Revenue reached a 15-quarter high of ₹1,300 crore, up 25% YoY and 10% QoQ.
PAT increased 41% YoY to ₹106 crore, with EPS rising to ₹6.7 from ₹4.7 in Q1 FY26.
Chemical Intermediates segment revenue grew 38% YoY to ₹524 crore with EBITDA margins jumping from 4% to 11%.
CDMO/Fine Chemicals pipeline stands at 100+ molecules with ₹3,500+ crore peak revenue potential.
Targeting ₹100 crore in annualized lean cost savings for FY27.
👀 What to Watch
Watch for the commissioning of the new Multi-Purpose Plant (MPP) by late 2026 and the ramp-up of the USD 300M+ CDMO contract which is critical for the 'Pinnacle 345' growth strategy.
41% PAT Growth: Jubilant Ingrevia Reports Strong Q1 FY27 with ₹1,300 Cr Revenue
Jubilant Ingrevia reported a strong start to FY27 with revenue growing 25% YoY to ₹1,300 crore, marking a 15-quarter high. Net profit surged 41% YoY to ₹106 crore, driven by a significant rebound in the Chemical Intermediates segment where EBITDA grew 240% YoY. EBITDA margins improved to 16% from 15% a year ago, supported by cost pass-through and a richer product mix in CDMO and Fine Chemicals. The company maintains a robust CDMO pipeline of 100+ molecules with a peak revenue potential of ₹3,500+ crore.
Confidence: HIGH
What changedThe company has moved past the pricing pressures of previous quarters, achieving double-digit growth across all three business segments simultaneously.
Why it mattersThe results validate the company's shift toward high-margin Specialty Chemicals and CDMO, with the Chemical Intermediates segment finally showing a strong margin recovery (11% vs 4% YoY).
Q1 Revenue: ₹1,300 CrQ1 PAT: ₹106 CrRevenue vs TTM Revenue: 29.6%CDMO Peak Revenue Potential: ₹3,500+ CrEBITDA Margin: 16%
📅 Short termThe stock is likely to react positively to the 41% PAT growth and the 15-quarter high revenue, reflecting improved operational efficiency.
📈 Long termStructural growth is supported by the ₹3,500 Cr CDMO pipeline and entry into high-tech semiconductor chemicals, which could significantly re-rate the business as these projects commercialize.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Geopolitical disruptions in the Middle East affecting supply chains
- Pricing pressure in the Pyridine portfolio
- Execution risk on the large-scale CDMO contract
Key Highlights
Revenue reached a 15-quarter high of ₹1,300 crore, representing 25% YoY and 10% QoQ growth.
PAT increased by 41% YoY to ₹106 crore, with EPS rising to ₹6.7 from ₹4.7 in Q1 FY26.
Chemical Intermediates EBITDA surged 240% YoY to ₹57 crore due to robust demand and price escalations.
CDMO pipeline includes 100+ molecules with a peak revenue potential exceeding ₹3,500 crore.
Nutrition segment EBITDA reached a 3-year high of ₹36 crore, up 45% YoY with 15% margins.
👀 What to Watch
Monitor the commissioning of the new Multi-Purpose Plant (MPP) scheduled for late 2026 and the ramp-up of the USD 300M+ CDMO contract which is critical for the 'Pinnacle 345' strategy.
